Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

responsive web design (RWD)

Reimagining the Patient Journey

Kimberly Tableman, CEO at Medicine X, discusses a myriad of topics related to digital transformation and patient centricity, including how digital health technologies can be used to reimagine the patient...

Impetus Digital

- PMLiVE

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health

If the heart of the medical affairs industry is ultimately improving patient outcomes, internal training is the regenerative liver. Med affairs professionals need to regularly update their scientific knowledge and...

OPEN Health

Environmental impact of in-person vs. virtual meetings

Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...

Impetus Digital

- PMLiVE

The US celebrates five years of biosimilars on the market – a look to the past, present and future

Why the success of biosimilars in the US has been mixed

- PMLiVE

PMEA 2020: continuing to recognise excellence in improving patient outcomes

The 20th annual PMEAs took place virtually this year due to COVID-19

- PMLiVE

BMS’ Opdivo wins EU approval for second-line oesophageal cancer

Competition heats up with rival checkpoint inhibitor Keytruda

- PMLiVE

Russia says its Sputnik V COVID-19 vaccine is 91.4% effective

Preliminary data demonstrates efficacy of 95% after 42 days

EU flag

EU buys 160 million doses of Moderna’s COVID-19 vaccine

Deal follows positive data readout last week

Roche Basel Switzerland

Roche’s Xofluza pill wins FDA approval for post-exposure flu prevention

First single-dose flu medication approved for post-exposure prophylaxis

- PMLiVE

The chief executive ostrich

Some of the most perplexing executive behaviour is simply Darwinian

Harness the power of data to map new patient pathways

Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset

Wilmington Healthcare

- PMLiVE

What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health

How fantastic is it to see that the National Organisation for Rare Disorders (NORD) has followed up on a survey undertaken in the late 80’s to pressure test progress and identify...

OPEN Health

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links